Sartorius Stedim Biotech S.A. Website

Sartorius Stedim Biotech S.A.

ENXTPA-DIM

Basic

  • Market Cap

    €15.98B

  • EV

    €18.48B

  • Shares Out

    97.31M

  • Revenue

    €2,746.9M

  • Employees

    10,382

Margins

  • Gross

    43.16%

  • EBITDA

    23.73%

  • Operating

    15.18%

  • Pre-Tax

    8.61%

  • Net

    6.17%

  • FCF

    11.1%

Returns (5Yr Avg)

  • ROA

    12.85%

  • ROTA

    37.58%

  • ROE

    24.82%

  • ROCE

    25.23%

  • ROIC

    16.91%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    €216.33

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    €454.1M

  • Net Debt

    €2,464.9M

  • Debt/Equity

    0.74

  • EBIT/Interest

    2.47

Growth (CAGR)

  • Rev 3Yr

    4.71%

  • Rev 5Yr

    15.51%

  • Rev 10Yr

    16.05%

  • Dil EPS 3Yr

    -29.3%

  • Dil EPS 5Yr

    -6.94%

  • Dil EPS 10Yr

    9.49%

  • Rev Fwd 2Yr

    6.93%

  • EBITDA Fwd 2Yr

    13.45%

  • EPS Fwd 2Yr

    10.9%

  • EPS LT Growth Est

    28%

Dividends

  • Yield

    —

  • Payout

    38.36%

  • DPS

    €0.69

  • DPS Growth 3Yr

    0.49%

  • DPS Growth 5Yr

    3.9%

  • DPS Growth 10Yr

    13.18%

  • DPS Growth Fwd 2Yr

    10.8%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

1,440.6

1,910.1

2,887

3,492.7

2,775.5

2,746.9

Total Revenues % Chg.

18.8%

32.6%

51.1%

21%

-20.5%

-13.4%

Cost of Goods Sold, Total

692.3

906.8

1,334

1,675.4

1,542

1,561.4

Gross Profit

748.3

1,003.3

1,553

1,817.3

1,233.5

1,185.5

Selling General & Admin Expenses, Total

317.6

391.8

531.9

612.3

617.8

636.2

R&D Expenses

79.2

84.5

110.5

132.4

129.5

134.2

Other Operating Expenses

3.5

23.9

-9.6

18.2

17.5

-1.8

Other Operating Expenses, Total

400.4

500.2

632.8

762.9

764.8

768.6

Operating Income

347.9

503.1

920.2

1,054.4

468.7

416.9

Interest Expense, Total

-3.9

-6.5

-10.2

-18.2

-115.4

-168.6

Interest And Investment Income

0.3

0.5

0.3

0.5

6.2

10.8

Net Interest Expenses

-3.5

-6

-9.9

-17.7

-109.2

-157.8

Currency Exchange Gains (Loss)

-11.7

-14.7

12.3

-32.8

-18.6

-18.6

Other Non Operating Income (Expenses)

1.5

1.1

-37.1

-4.6

0.6

0.7

EBT, Excl. Unusual Items

334.2

483.6

885.5

999.3

341.5

241.2

Restructuring Charges

—

—

—

—

—

—

—

—

—

—

Merger & Related Restructuring Charges

—

—

—

—

-0.3

-4.3

-20.3

—

—

—

Other Unusual Items

—

-16.5

-18.6

-218.5

131.1

59.6

-4.8

EBT, Incl. Unusual Items

317.4

460.7

646.7

1,130.4

401.1

236.4

Income Tax Expense

81.4

122.1

232.4

250.5

89

63

Earnings From Continuing Operations

236

338.6

414.3

879.9

312.1

173.4

Minority Interest

-1.5

-2.7

0.1

-3.8

-2.4

-3.9

Net Income

234.5

335.9

414.4

876.1

309.7

169.5

Net Income to Common Incl Extra Items

234.5

335.9

414.4

876.1

309.7

169.5

Net Income to Common Excl. Extra Items

234.5

335.9

414.4

876.1

309.7

169.5

Total Shares Outstanding

92.2

92.2

92.2

92.2

92.2

95.2

Weighted Avg. Shares Outstanding

92.2

92.2

92.2

92.2

92.2

94.2

Weighted Avg. Shares Outstanding Dil

92.2

92.2

92.2

92.2

92.2

94.2

EPS

2.5

3.6

4.5

9.5

3.4

1.8

EPS Diluted

2.5

3.6

4.5

9.5

3.4

1.8

EBITDA

401.5

577.3

1,031.4

1,196.9

657.8

651.9

Effective Tax Rate

25.6%

26.5%

35.9%

22.2%

22.2%

26.6%